U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYTARABINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

HIDE SMILES / InChI
Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

CNS Active
4002

Originator

University of California-Berkeley
3
Curator's Comment: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-­Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.

Approval Year

1969
24
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
665
Unknown

Approved Use

Unknown
Lymphomatous meningitis
3
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
 Primary
Approved
8583
CYTARABINE

Approved Use

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.

Launch Date

1969
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1900 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80 h
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/12162758
50 mg single, intrathecal
dose: 50 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
CYTARABINE cerebrospinal fluid
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Disc. AE: Cerebellar disorder NOS, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 66.7%)
Diarrhea (grade 3, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 33.3%)
Cerebellar disorder NOS (grade 5, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
3 g/m2 2 times / day multiple, intravenous
MTD
Dose: 3 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 3 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Disc. AE: Bone marrow depression, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Leukopenia
Thrombocytopenia
Anemia
Nausea
Vomiting
Diarrhea
Abdominal pain
Oral ulceration
Hepatic dysfunction NOS
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Cerebellar disorder NOS grade 4, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Cerebellar disorder NOS grade 4, 33.3%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Cerebellar disorder NOS grade 5, 16.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
unhealthy, 16-76
Health Status: unhealthy
Age Group: 16-76
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Abdominal pain Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Anemia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Bone marrow depression Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Diarrhea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Hepatic dysfunction NOS Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Leukopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Nausea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Oral ulceration Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Thrombocytopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Vomiting Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 yes [IC50 6.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28680
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28680
eMolecules
1012736
https://www.emolecules.com/cgi-bin/more?vid=1012736
MolPort
MolPort-001-792-509
https://www.molport.com/shop/molecule-link/MolPort-001-792-509
Selleck Chemicals
Cytarabine(Cytosar-U)
http://www.selleckchem.com/products/Cytarabine(Cytosar-U).html
ZINC
ZINC000003795098
http://zinc15.docking.org/substances/ZINC000003795098
PubMed

PubMed

TitleDatePubMed
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
2001-04-15
Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells.
2001-04-15
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
2001-04-11
Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
2001-04-11
The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway.
2001-04-01
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
2001-04-01
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
2001-04-01
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents.
2001-04-01
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
2001-04
Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp.
2001-04
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
2001-04
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
2001-04
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001-04
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.
2001-03-30
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
2001-03-15
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
2001-03-15
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
2001-03-02
Severe hepatic injury associated with lipid formulations of amphotericin B.
2001-03-01
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
2001-03
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
2001-03
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
2001-03
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
2001-03
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
2001-03
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
2001-03
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
2001-03
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
2001-03
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
2001-03
Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
2001-02-24
Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
2001-02-24
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
2001-02-16
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
2001-02-15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001-02-15
Therapy of acute myeloid leukemia.
2001-02-15
[Palpable mantel cell lymphoma in the breast].
2001-02-03
[Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C].
2001-02
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
2001-02
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
2001-02
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
2001-02
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
2001-02
Bilateral breast relapse in acute myelogenous leukemia.
2001-02
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
2001-02
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
2001-02
Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.
2001-02
Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
2001-01-01
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
2001-01-01
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.
2001-01
The biology and treatment of chronic myelogenous leukemia.
2001-01
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
2001-01
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].
2001-01
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.
2001-01
Patents

Patents

03950325
3
JP2000512843A
3
JP2004518776A
9
JP2006502184A
41
JP2006521885A
8
JP2006523256A
8
JP2007533670A
6
JP2008245583A
3
JP2008510795A
76
JP2008533019A
34
JP2011500014A
3
JP2011528275A
456
JP2012500104A
108
JP4395065B2
11
JP4397691B2
21
JPH05186354A
4
JPH05310819A
3
JPS05537166A
3
JPS527975A
3
JPS5665829A
3

Sample Use Guides

In Vivo Use Guide
Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration: Intratracheal
In Vitro Use Guide
Curator's Comment: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:11:33 GMT 2025
Edited
by admin
on Wed Apr 02 08:11:33 GMT 2025
Record UNII
04079A1RDZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTARABINE LIPOSOME
VANDF  
Preferred Name English
CYTARABINE
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CYTARABINE [USP-RS]
Common Name English
CYTARABINE [HSDB]
Common Name English
CYTOSAR-U
Brand Name English
CYTARABINE [EP MONOGRAPH]
Common Name English
CYTARABINE [WHO-IP]
Common Name English
CYTARABINUM [WHO-IP LATIN]
Common Name English
DEPOCYT
Brand Name English
ARACYTIN
Common Name English
U-19,920
Code English
CYTARABINE [USAN]
Common Name English
CYTARABINE [VANDF]
Common Name English
ARACYTIDINE
Common Name English
SPONGOCYTIDINE
Common Name English
CYTARABINE [MI]
Common Name English
ARABINOCYTOSINE
Common Name English
CYTARABINE [ORANGE BOOK]
Common Name English
ARA-C
Common Name English
CYTARABINE LIPOSOME [VANDF]
Common Name English
CYTARABINE [USP IMPURITY]
Common Name English
1-.BETA.-D-ARABINOFURANOSYLCYTOSINE
Common Name English
Cytarabine [WHO-DD]
Common Name English
VYXEOS COMPONENT CYTARABINE
Brand Name English
NSC-287459
Code English
U 19920A
Common Name English
CYTARABINE [MART.]
Common Name English
CYTARABINOSIDE
Common Name English
CYTARABINE [JAN]
Common Name English
U-19920
Code English
ARACYTINE
Common Name English
cytarabine [INN]
Common Name English
CYTARABINE [EMA EPAR]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-
Common Name English
CYTARABINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XY01
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
FDA ORPHAN DRUG 234806
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
NDF-RT N0000175595
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
NDF-RT N0000000233
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
EMA ASSESSMENT REPORTS DEPOCYT (AUTHORIZED: MENINGEAL NEOPLASMS)
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
FDA ORPHAN DRUG 265808
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
NCI_THESAURUS C1557
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
FDA ORPHAN DRUG 73393
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
LIVERTOX NBK548291
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
WHO-ATC L01BC01
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
EU-Orphan Drug EU/3/11/942
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
WHO-VATC QL01BC01
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
Code System Code Type Description
RXCUI
968804
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
ALTERNATIVE
ECHA (EC/EINECS)
205-705-9
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID3022877
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
DRUG BANK
DB00987
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
EVMPD
SUB06880MIG
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
NCI_THESAURUS
C408
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
RXCUI
3041
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
DAILYMED
04079A1RDZ
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
MERCK INDEX
m4051
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY Merck Index
PUBCHEM
6253
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
WIKIPEDIA
CYTARABINE
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
ChEMBL
CHEMBL803
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
RS_ITEM_NUM
1162002
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
FDA UNII
04079A1RDZ
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
IUPHAR
4827
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
DRUG CENTRAL
770
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
CAS
147-94-4
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
MESH
D003561
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
CHEBI
28680
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
SMS_ID
100000089874
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
INN
1709
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
HSDB
3049
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
NSC
287459
Created by admin on Wed Apr 02 08:11:33 GMT 2025 , Edited by admin on Wed Apr 02 08:11:33 GMT 2025
PRIMARY
Related Record Type Details
DEOXYCYTIDINE KINASE
METABOLIC ENZYME -> SUBSTRATE
kcat
DEOXYCYTIDINE KINASE
METABOLIC ENZYME -> SUBSTRATE
Km
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of CYTARABINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ASPACYTARABINE
PRODRUG -> METABOLITE ACTIVE
Structure of URACIL ARABINOSIDE
METABOLITE INACTIVE -> PARENT
Produced via Cytidine deaminase exposure.
PLASMA
Structure of ELACYTARABINE
PRODRUG -> METABOLITE ACTIVE
Structure of CYTIDINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of CYTARABINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of URACIL ARABINOTIDE
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of CYTARABINE 5'-PHOSPHATE
METABOLITE -> PARENT
Related Record Type Details
Structure of CYTIDINE
IMPURITY -> PARENT
Structure of Cytosine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL ARABINOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL ARABINOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of URACIL
IMPURITY -> PARENT
Structure of 5-METHYLCYTIDINE
IMPURITY -> PARENT
Structure of ANCITABINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URIDINE
IMPURITY -> PARENT
Structure of URACIL
IMPURITY -> PARENT
Related Record Type Details
Structure of CYTARABINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966